Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. More Details
Moderate growth potential and slightly overvalued.
Share Price & News
How has Bausch Health Companies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BHC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BHC's weekly volatility (5%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: BHC exceeded the US Pharmaceuticals industry which returned 20% over the past year.
Return vs Market: BHC exceeded the US Market which returned 44.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Bausch Health Companies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAmy Wechsler Is The Independent Director of Bausch Health Companies Inc. (NYSE:BHC) And They Just Sold 100% Of Their Shares
2 weeks ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Bausch Health Companies Inc.'s (NYSE:BHC) Shares?
1 month ago | Simply Wall StThis Is Why Bausch Health Companies Inc.'s (NYSE:BHC) CEO Compensation Looks Appropriate
Is Bausch Health Companies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BHC ($31.82) is trading below our estimate of fair value ($144.56)
Significantly Below Fair Value: BHC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BHC is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: BHC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BHC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BHC has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.
How is Bausch Health Companies forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BHC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: BHC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BHC's is expected to become profitable in the next 3 years.
Revenue vs Market: BHC's revenue (3.4% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: BHC's revenue (3.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BHC's Return on Equity is forecast to be high in 3 years time
How has Bausch Health Companies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BHC is currently unprofitable.
Growing Profit Margin: BHC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BHC is unprofitable, and losses have increased over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare BHC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BHC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.3%).
Return on Equity
High ROE: BHC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Bausch Health Companies's financial position?
Financial Position Analysis
Short Term Liabilities: BHC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BHC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BHC has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BHC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BHC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BHC is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 13.9% per year.
What is Bausch Health Companies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BHC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BHC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BHC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: BHC is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BHC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joe Papa (64 yo)
Mr. Joseph C. Papa, also known as Joe, serves as an Independent Director of Prometheus Biosciences, Inc since August 2020. He has been the Chairman of the Board and Chief Executive Officer of Bausch Health...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD14.12M) is about average for companies of similar size in the US market ($USD11.17M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Experienced Management: BHC's management team is considered experienced (4.5 years average tenure).
Experienced Board: BHC's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BHC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bausch Health Companies Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Bausch Health Companies Inc.
- Ticker: BHC
- Exchange: NYSE
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$11.404b
- Shares outstanding: 358.40m
- Website: https://www.bauschhealth.com
Number of Employees
- Bausch Health Companies Inc.
- 2150 St. ElzEar Boulevard West
- H7L 4A8
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenter...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/14 02:30|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.